CoChat
Sign Up
Cited by 431Treatment of Major DepressionMental Health Treatment and AccessAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 148 of the 150 references it cites were found in a registry or an index.

Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.

Lam, Raymond W., Kennedy, Sidney H., Grigoriadis, Sophie, McIntyre, Roger S., Milev, Roumen, Ramasubbu, Rajamannar, Parikh, Sagar V., Patten, Scott B., Ravindran, Arun V.·2009·Journal of Affective Disorders
DOI 10.1016/j.jad.2009.06.041
Open this paper in CoChat — free account

Abstract

Background In 2001, the Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT) partnered to produce evidence-based clinical guidelines for the treatment of depressive disorders. A revision of these guidelines was undertaken by CANMAT in 2008-2009 to reflect advances in the field. Methods The CANMAT guidelines are based on a question-answer format to enhance accessibility to clinicians. An evidence-based format was used with updated systematic reviews of the literature and recommendations were graded according to Level of Evidence using pre-defined criteria. Lines of Treatment were identified based on criteria that included Levels of Evidence and expert clinical support. This section on "Pharmacotherapy" is one of 5 guideline articles. Results Despite emerging data on efficacy and tolerability differences amongst newer antidepressants, variability in patient response precludes identification of specific first choice medications for all patients. All second-generation antidepressants have Level 1 evidence to support efficacy and tolerability and most are considered first-line treatments for MDD. First-generation tricyclic and monoamine oxidase inhibitor antidepressants are not the focus of these guidelines but generally are considered second- or third-line treatments. For inadequate or incomplete response, there is Level 1 evidence for switching strategies and for add-on strategies including lithium and atypical antipsychotics. Limita…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jad.2009.06.041

Cites

148 of 148 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

2 of the 150 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Lam, 2004, Prescribing antidepressants for depression in 2005: recent concerns and recommendations, Can. J. Psychiatry, 49, 1

Cited by

Sorted by citations

See all 431

Related

See all

Metadata

Authors
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V.
Affiliations
  • University of British Columbia (CA)
  • University of Toronto (CA)
  • Queen's University (CA)
  • University of Calgary (CA)
Corresponding author
Lam, Raymond W.
ORCID
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2009-10
Volume
117
Pages
S26-S43
ISSN
0165-0327 (ISSN-L)
DOI
10.1016/j.jad.2009.06.041
OpenAlex
W38793130
Cited by
431
References
150
Citations by year
2026: 6 · 2025: 4 · 2024: 8 · 2023: 9 · 2022: 13 · 2021: 15 · 2020: 16 · 2019: 18 · 2018: 24 · 2017: 27 · 2016: 41 · 2015: 55 · 2014: 43 · 2013: 49 · 2012: 55
FWCI
24.76
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Affective Disorders (publishedVersion)
  • PubMed (publishedVersion)
Funders
Canadian Network for Mood and Anxiety Treatments
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
major depressive disorder, antidepressant treatment, second-generation antidepressants, first-line therapy, inadequate response, switching strategy, adjunctive therapy, lithium, atypical antipsychotics, tricyclic antidepressants, monoamine oxidase inhibitors, treatment-resistant depression, adults
MeSH terms
Suicide Prevention, Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Drug Interactions, Humans, Sexual Dysfunction, Physiological, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review